We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol
Read MoreHide Full Article
PerkinElmer, Inc. recently announced that its Hand Sanitizer Analyzer instrument can be utilized to test the presence of methanol in alcohol-based hand sanitizer products with pass/fail results outcome delivered in 30 seconds or less.
Notably, the Hand Sanitizer Analyzer is part of PerkinElmer’s comprehensive portfolio of solutions, helping lab professionals and scientists all over the world in their fight against COVID-19.
This instrument is likely to boost the company’s Human Health operating segment.
More About PerkinElmer’s Hand Sanitizer Analyzer
In recent times, there have been warnings and recalls from the FDA, indicating that methanol can be toxic to consumers if absorbed through the skin and life threatening if ingested. The Hand Sanitizer Analyzer instrument, commercially launched in April 2020, also tests hand sanitizers for concentration levels of desired alcohols, such as ethanol and isopropanol, to help ensure compliance with WHO, USP or FDA guidelines.
The compact and portable analyzer is based on the company’s Spectrum Two FT-IR spectrometer solution. The underlying technology enables quick detection of methanol contamination down to 0.03% (or 300 parts per million), which is more sensitive than the FDA-mandated detection limits.
With the COVID-19 pandemic continuing, it is essential that consumers trust the safety and proficiency of alcohol-based hand sanitizer products. The PerkinElmer Hand Sanitizer Analyzer delivers swift and reliable results to producers and suppliers of these high-demand products, protecting consumers and avoiding counterfeit ingredient use and recalls.
Recent Developments
Lately, PerkinElmer has been making a plethora of product launches to expedite its fight against COVID-19.
In August 2020, the company launched a series of scalable and modular explorer workstations for SARS-CoV-2 testing, equipped to prepare and conduct up to 10,000 COVID-19 tests per day. These modular and scalable workstations will help laboratories boost SARS-CoV-2 testing capacity and deliver results swiftly.
In July, the company launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 27.3% compared with the industry’s growth of 22.5%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space include OPKO Health (OPK - Free Report) , Surmodics (SRDX - Free Report) and Merit Medical Systems (MMSI - Free Report) .
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Merit Medical Systems’ long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
PerkinElmer's Hand Sanitizer Analyzer to Test for Methanol
PerkinElmer, Inc. recently announced that its Hand Sanitizer Analyzer instrument can be utilized to test the presence of methanol in alcohol-based hand sanitizer products with pass/fail results outcome delivered in 30 seconds or less.
Notably, the Hand Sanitizer Analyzer is part of PerkinElmer’s comprehensive portfolio of solutions, helping lab professionals and scientists all over the world in their fight against COVID-19.
This instrument is likely to boost the company’s Human Health operating segment.
More About PerkinElmer’s Hand Sanitizer Analyzer
In recent times, there have been warnings and recalls from the FDA, indicating that methanol can be toxic to consumers if absorbed through the skin and life threatening if ingested. The Hand Sanitizer Analyzer instrument, commercially launched in April 2020, also tests hand sanitizers for concentration levels of desired alcohols, such as ethanol and isopropanol, to help ensure compliance with WHO, USP or FDA guidelines.
The compact and portable analyzer is based on the company’s Spectrum Two FT-IR spectrometer solution. The underlying technology enables quick detection of methanol contamination down to 0.03% (or 300 parts per million), which is more sensitive than the FDA-mandated detection limits.
With the COVID-19 pandemic continuing, it is essential that consumers trust the safety and proficiency of alcohol-based hand sanitizer products. The PerkinElmer Hand Sanitizer Analyzer delivers swift and reliable results to producers and suppliers of these high-demand products, protecting consumers and avoiding counterfeit ingredient use and recalls.
Recent Developments
Lately, PerkinElmer has been making a plethora of product launches to expedite its fight against COVID-19.
In August 2020, the company launched a series of scalable and modular explorer workstations for SARS-CoV-2 testing, equipped to prepare and conduct up to 10,000 COVID-19 tests per day. These modular and scalable workstations will help laboratories boost SARS-CoV-2 testing capacity and deliver results swiftly.
In July, the company launched a dry blood spot (DBS)-based test for SARS-CoV-2 IgG using its GSP/DELFIA platform. The platform enables processing of up to 5,000 samples per day. The finger-prick sample collection device facilitates both decentralized sample collection and high-throughput testing.
Market Prospects
Per a report published on Grand View Research, the global molecular diagnostics market was valued at $9.2 billion in 2019 and is expected to reach $18.2 billion by 2027, at a CAGR of 9%. Hence, the latest development has been a well-timed one for PerkinElmer.
Price Performance
Over the past three months, shares of the company have gained 27.3% compared with the industry’s growth of 22.5%.
Zacks Rank and Other Key Picks
PerkinElmer currently sports a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks from the broader medical space include OPKO Health (OPK - Free Report) , Surmodics (SRDX - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health’s long-term earnings growth rate is estimated at 12%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Surmodics’ long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Merit Medical Systems’ long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>